XML 185 R119.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaborative and Other Relationships (Details Textual) shares in Millions, $ in Millions, ₩ in Billions | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 29, 2012 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2018 KRW (₩) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Jun. 30, 2017 USD ($) | Dec. 31, 2013 USD ($) | Sep. 30, 2013 | Dec. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2019 KRW (₩) | Dec. 31, 2018 KRW (₩) | Nov. 07, 2018 USD ($) | Jun. 05, 2018 USD ($) shares | Sep. 30, 2017 | Mar. 31, 2016 | Dec. 31, 2012 USD ($) | Feb. 29, 2012 KRW (₩)
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,280.6 | $ 2,597.2 | $ 2,253.6 |  |  |  |  |  |  |  |  |
Product Revenues |  | $ 3,671.3 | $ 3,600.1 | $ 3,616.7 | $ 3,489.8 | $ 3,526.3 |  | $ 3,439.0 | $ 3,356.5 | $ 3,131.1 |  |  |  |  |  | 14,377.9 | 13,452.9 | 12,273.9 |  |  |  |  |  |  |  |  |
Cost of Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,955.4 | 1,816.3 | 1,630.0 |  |  |  |  |  |  |  |  |
Collaboration profit (loss) sharing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 241.6 | 185.0 | 112.3 |  |  |  |  |  |  |  |  |
Potential future milestone payments commitment, approximately |  | 6,800.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,800.0 |  |  |  |  |  |  |  |  |  |  |
Prepaid research and development |  | 1,252.8 |  |  |  | 1,690.6 |  |  |  |  |  |  |  |  | $ 1,690.6 | 1,252.8 | 1,690.6 |  |  |  |  |  |  |  |  |  |
Payments to increase investment in Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.0 | 676.6 | 0.0 |  |  |  |  |  |  |  |  |
Equity in loss of investee, net of tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (79.4) | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
Ionis Pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected additional milestone payments when certain sales threshold is met |  | 800.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 800.0 |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  | 324.1 |  |  |  |  |  |  | 30.0 |  |  | $ 10.0 |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 260.0 |  |  |  |  |  |  |  |  |  |  |
Net change in acquired and in-licensed rights and patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150.0 |  |  |  |  |  |  |  |  |
License Fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70.0 |  |  |  |  |  |  |  |  |  |  |
Expected License Fee And Regulatory Milestone Payments |  | 130.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 130.0 |  |  |  |  |  |  |  |  |  |  |
Upfront payment for collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 375.0 |  |  | $ 30.0 |
Investment in common stock, shares purchased | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11.5 |  |  |  |
Upfront And Milestone Payments Made To Collaborative Partner |  |  |  |  |  |  |  |  |  |  | $ 25.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense asset acquired |  | 45.0 |  |  |  |  |  |  | $ 486.2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payment |  | 155.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 155.0 |  |  |  |  |  |  |  |  |  | $ 10.0 |
Term of collaboration agreement |  |  |  |  |  |  |  |  | 10 |  |  |  |  | six |  |  |  |  |  |  |  |  |  |  |  |  |
Total payment to enter collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000.0 |  |  |  |
Prepaid research and discovery services |  |  |  |  |  |  |  |  | $ 50.9 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 625.0 |  |  |  |
Premium on purchase of common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 162.1 |  |  |  |
Investment in common stock, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 462.9 |  |  |  |
Ionis Pharmaceuticals | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125.0 |  |  |  |  |  |  |  |  |  |  |
Ionis Pharmaceuticals | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 270.0 |  |  |  |  |  |  |  |  |  |  |
Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen's share of expense reflected within our consolidation statements of income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 174.3 | 116.0 | 74.3 |  |  |  |  |  |  |  |  |
BAN2401 and Elenbecestat R&D expense incurred by collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 348.7 | 232.0 | 146.2 |  |  |  |  |  |  |  |  |
Percentage of future development costs related to Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% | 45.00% |  |  |  |  |  |  |  |  |  |  |
Loss on Contract Termination |  |  | $ 48.0 |  | 45.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Alkermes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  | 50.0 |  |  |  |  | $ 53.5 | 68.7 | 80.3 |  |  |  |  |  |  |  |  |
Upfront And Milestone Payments Made To Collaborative Partner |  |  |  |  |  |  |  |  |  |  | $ 28.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future milestone payments commitment, approximately |  | 155.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 155.0 |  |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  | $ 300.0 |  |  |  | 144.0 | 97.0 |  |  |  |  |  |  |  |  |  |
Additional milestone payment |  | 360.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 360.0 |  |  |  |  |  |  |  |  |  |  |
iPerian |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payment |  | 370.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 370.0 |  |  |  |  |  |  |  |  |  |  |
Developmental Milestone Payment |  |  |  |  |  |  |  |  |  |  |  | $ 60.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acorda |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen's share of expense reflected within our consolidation statements of income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 42.0 | 36.5 | 34.0 |  |  |  |  |  |  |  |  |
Expected additional milestone payments when certain sales threshold is met |  | 15.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.0 |  |  |  |  |  |  |  |  |  |  |
Foreign sales required to trigger milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100.0 |  |  |  |  |  |  |  |  |  |  |
AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Skyhawk Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront And Milestone Payments Made To Collaborative Partner |  | 15.0 |  |  | 74.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense asset acquired |  | 8.0 |  |  | 38.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payment |  | 2,400.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,400.0 |  |  |  |  |  |  |  |  |  |  |
Prepaid research and discovery services |  | 7.0 |  |  | $ 35.5 |  |  |  |  |  |  |  |  |  |  | 7.0 |  |  |  |  |  |  |  |  |  |  |
Other research and discovery |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.6 | 22.0 | 10.0 |  |  |  |  |  |  |  |  |
Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  | $ 46.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 210.0 |  |  |  |  |  |  |  |  |  |  |
Contract Option Exercise Fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60.0 |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 106.2 | 96.4 | 42.7 |  |  |  |  |  |  |  |  |
Collaboration profit (loss) sharing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 241.6 | 187.4 | $ 111.0 |  |  |  |  |  |  |  |  |
Upfront And Milestone Payments Made To Collaborative Partner |  | 100.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense asset acquired |  | 63.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prepaid research and discovery services |  | 37.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 37.0 |  |  |  |  |  |  |  |  |  |  |
Equity Method Investments, Expected Profit Share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Due from Related Parties |  | 85.0 |  |  |  | 116.9 |  |  |  |  |  |  |  |  | $ 116.9 | $ 85.0 | 116.9 |  |  |  |  |  |  |  |  |  |
Due to Related Parties |  | $ 100.0 |  |  |  | $ 31.5 |  |  |  |  |  |  |  |  | $ 31.5 | $ 100.0 | $ 31.5 |  |  |  |  |  |  |  |  |  |
RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Co promotion Operating Profits first fifty million |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  | 30.00% |  |  |  |  |  |  |
Until First GAZYVA Threshold Date |  | 39.00% |  |  |  |  |  |  |  |  | 37.50% |  |  |  |  | 39.00% |  | 37.50% |  | 39.00% |  |  |  |  | 39.00% |  |
Until GAZYVA First Non-CLL FDA Approval |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  | 40.00% |  |  |  | 40.00% |  |  |  |  |  |  |
After First Threshold Date and until Second Threshold Date |  | 37.50% |  |  |  | 37.50% |  |  |  |  |  |  |  |  | 37.50% | 37.50% | 37.50% |  |  | 37.50% | 37.50% |  |  | 37.50% |  |  |
GAZYVA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Co promotion Operating Profits first fifty million |  | 35.00% |  |  |  |  |  |  |  |  | 35.00% |  |  |  |  | 35.00% |  | 35.00% |  | 35.00% |  |  |  |  |  |  |
Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment |  | $ 50.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50.0 |  |  |  |  |  |  |  |  |  |  |
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150.0 |  |  |  |  |  |  |  |  |  |  |
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150.0 |  |  |  |  |  |  |  |  |  |  |
Sales Trigger Gross Sales Threshold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500.0 |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date |  | 39.00% |  |  |  |  |  |  |  |  |  |  |  |  |  | 39.00% |  |  |  | 39.00% |  |  |  |  |  |  |
After First Threshold Date and until Second Threshold Date |  | 37.50% |  |  |  |  |  |  |  |  |  |  |  |  |  | 37.50% |  |  |  | 37.50% |  |  |  |  |  |  |
New Anti-CD20 | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future percentage of co-promotion operating profits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |
New Anti-CD20 | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future percentage of co-promotion operating profits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37.50% |  |  |  |  |  |  |  |  |  |  |
OCREVUS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty operating profit threshold for highest royalty rate percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 900.0 |  |  |  |  |  |  |  |  |  |  |
Reduction in royalty rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Period of collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 years |  |  |  |  |  |  |  |  |  |  |
OCREVUS | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future royalties percentage to be received on sale of ocrelizumab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13.50% |  |  |  |  |  |  |  |  |  |  |
OCREVUS | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future royalties percentage to be received on sale of ocrelizumab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24.00% |  |  |  |  |  |  |  |  |  |  |
ZINBRYTA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.0 | $ 1.4 | $ 52.7 |  |  |  |  |  |  |  |  |
Unrecorded tax benefit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 93.8 |  |  |  |  |  |  |  |  |
ZINBRYTA | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen's share of expense reflected within our consolidation statements of income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.3 | 16.2 | 19.9 |  |  |  |  |  |  |  |  |
SPINRAZA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,097.0 | 1,724.2 | 883.7 |  |  |  |  |  |  |  |  |
SPINRAZA | Ionis Pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,097.0 | 1,724.2 | 883.7 |  |  |  |  |  |  |  |  |
Cost of Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 293.0 | 238.0 | 112.4 |  |  |  |  |  |  |  |  |
SPINRAZA | Ionis Pharmaceuticals | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Royalties As Per Collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11.00% |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | Ionis Pharmaceuticals | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Royalties As Per Collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |
SOD1 | Ionis Pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20.0 | 18.0 | 12.0 |  |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55.0 |  |  |  |  |  |  |  |  |  |  |
Upfront And Milestone Payments Made To Collaborative Partner |  |  |  |  |  | $ 35.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
VUMERITY |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5.5 | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
Net change in acquired and in-licensed rights and patents |  | $ 155.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
VUMERITY | Alkermes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Royalties As Per Collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |
Biosimilars |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 738.3 | 545.1 | 379.8 |  |  |  |  |  |  |  |  |
IMRALDI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 184.0 | 16.7 | 0.0 |  |  |  |  |  |  |  |  |
Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net change in acquired and in-licensed rights and patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75.0 |  |  |  |  |  |  |  |  |
Additional milestone payment |  |  |  |  |  | 25.0 |  |  |  |  |  |  |  |  | $ 25.0 |  | 25.0 |  |  |  |  |  |  |  |  |  |
Investments By Third Party In Joint Venture As Per Agreement. | $ 250.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ₩ 280.5
Joint Venture Owner Ship Percentage By Third Party. | 85.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment in Samsung Bioepis | $ 45.0 | $ 580.2 |  |  |  | 680.6 |  |  |  |  |  |  |  |  | $ 680.6 | $ 580.2 | $ 680.6 |  |  | ₩ 670.8 | ₩ 759.5 |  |  |  |  |  | ₩ 49.5
Samsung Bioepis, ownership percentage | 15.00% | 49.90% |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.90% |  |  |  | 49.90% |  |  |  |  |  |  | 15.00%
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 675.0 |  |  |  |  |
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 79.4 |  |  |  |  |  |  |  |  |  |  |
Payments to increase investment in Samsung Bioepis |  |  |  |  |  | $ 676.6 | ₩ 759.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Samsung Bioepis, ownership percentage before additional purchase transaction |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  | 5.00% |  | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Equity in loss of investee, net of tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.2 |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (78.2) |  |  |  |  |  |  |  |  |  |  |
Research and development | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BAN2401 and Elenbecestat R&D expense incurred by collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.6 | $ 32.4 | 39.9 |  |  |  |  |  |  |  |  |
Selling, general and administrative | Aducanumab [Member] | Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen's share of expense reflected within our consolidation statements of income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.2 | 5.4 | 0.0 |  |  |  |  |  |  |  |  |
BAN2401 and Elenbecestat expense incurred by the collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 32.4 | 10.7 | 0.0 |  |  |  |  |  |  |  |  |
U.S | Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |  |  |  |  |
U.S | ZINBRYTA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.0 | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
U.S | SPINRAZA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 933.4 | 854.0 | 657.0 |  |  |  |  |  |  |  |  |
U.S | VUMERITY |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.5 | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
U.S | Biosimilars |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.0 | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
U.S | IMRALDI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.0 | 0.0 | 0.0 |  |  |  |  |  |  |  |  |
Outside the U.S | OCREVUS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future royalties percentage to be received on sale of ocrelizumab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |
European Union | Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 68.50% |  |  |  |  |  |  |  |  |  |  |
JAPAN | Eisai |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |
AbbVie | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.0 | (8.6) | (16.9) |  |  |  |  |  |  |  |  |
AbbVie | U.S | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (8.6) | $ (16.9) |  |  |  |  |  |  |  |  |
Inventories | Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115.0 |  |  |  |  |
Equity method investment basis difference amortization period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year 6 months |  |  |  |  |  |  |  |  |  |  |
Completed technology | Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 615.0 |  |  |  |  |
Equity method investment basis difference amortization period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |  |
In-process research and development | Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 170.0 |  |  |  |  |
Deferred tax liability | Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 225.0 |  |  |  |  |
Development Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future milestone payments commitment, approximately |  | $ 1,200.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200.0 |  |  |  |  |  |  |  |  |  |  |
Development Milestones | Samsung Bioepis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payment |  | $ 15.0 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15.0 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Biogen share of co-promotion profits or losses + References No definition available. + Details
Name: | biib_Biogenshareofcopromotionprofitsorlosses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment. + References No definition available. + Details
Name: | biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase. + References No definition available. + Details
Name: | biib_CollaborationProfitSharing
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborations. + References No definition available. + Details
Name: | biib_CollaborationsTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract Option Exercise Fee + References No definition available. + Details
Name: | biib_ContractOptionExerciseFee
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Developmental Milestone Payment + References No definition available. + Details
Name: | biib_DevelopmentalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction + References No definition available. + Details
Name: | biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Method Investments, Expected Profit Share + References No definition available. + Details
Name: | biib_EquityMethodInvestmentsExpectedProfitShare
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity method investment basis difference amortization period + References No definition available. + Details
Name: | biib_Equitymethodinvestmentbasisdifferenceamortizationperiod
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Estimated additional payments upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expected additional milestone payments when meeting certain sales threshold. + References No definition available. + Details
Name: | biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Expected license fee and regulatory milestone payments. + References No definition available. + Details
Name: | biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total expense incurred by collaboration. + References No definition available. + Details
Name: | biib_ExpenseIncurredByCollaboration
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense incurred by the collaboration + References No definition available. + Details
Name: | biib_Expenseincurredbythecollaboration
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense reflected within statements of income + References No definition available. + Details
Name: | biib_Expensereflectedwithinstatementsofincome
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Foreign sales required to trigger milestone. + References No definition available. + Details
Name: | biib_ForeignSalesRequiredToTriggerMilestone
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future royalties percentage to be received on sale of product. + References No definition available. + Details
Name: | biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future percentage of co-promotion operating profits + References No definition available. + Details
Name: | biib_Futurepercentageofcopromotionoperatingprofits
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investment in common stock, shares purchased + References No definition available. + Details
Name: | biib_Investmentincommonstocksharespurchased
Namespace Prefix: | biib_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Investment in common stock, value + References No definition available. + Details
Name: | biib_Investmentincommonstockvalue
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Investments by third party in joint venture as per agreement + References No definition available. + Details
Name: | biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Joint venture owner ship percentage by third party. + References No definition available. + Details
Name: | biib_JointVentureOwnerShipPercentageByThirdParty
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Fee + References No definition available. + Details
Name: | biib_LicenseFee
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of co promotion operating profits first fifty million. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of royalties as per collaboration. + References No definition available. + Details
Name: | biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future development costs related to Eisai + References No definition available. + Details
Name: | biib_PercentageoffuturedevelopmentcostsrelatedtoEisai
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Of Collaboration Agreement + References No definition available. + Details
Name: | biib_PeriodOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Premium on purchase of common stock + References No definition available. + Details
Name: | biib_Premiumonpurchaseofcommonstock
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Purchase of common stock + References No definition available. + Details
Name: | biib_Purchaseofcommonstock
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Reduction in royalty rate + References No definition available. + Details
Name: | biib_Reductioninroyaltyrate
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty operating profit threshold for highest royalty rate percentage + References No definition available. + Details
Name: | biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales trigger gross sales threshold. + References No definition available. + Details
Name: | biib_SalesTriggerGrossSalesThreshold
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of collaboration agreement + References No definition available. + Details
Name: | biib_Termofcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one. + References No definition available. + Details
Name: | biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Threshold of gross sales to be achieved in any twelve consecutive months under option one. + References No definition available. + Details
Name: | biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total payment to enter collaboration agreement + References No definition available. + Details
Name: | biib_Totalpaymenttoentercollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total upfront and milestone payments made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment for collaboration agreement + References No definition available. + Details
Name: | biib_Upfrontpaymentforcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10(3)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.3) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_DueToRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The loss recognized on termination of a contract. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 275 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401 + Details
Name: | us-gaap_LossOnContractTermination
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of noncurrent assets classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + References No definition available. + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319 + Details
Name: | us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AlkermesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_IPerianMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AcordaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_RituxanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_GAZYVAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_NewAntiCd20Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_OCREVUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_ZINBRYTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_SPINRAZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_SOD1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_VUMERITYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_BiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_IMRALDIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_E2609andBAN2401Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=biib_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |